← Back to headlines
Regeneron Stock Falls After Melanoma Trial Failure
Regeneron Pharmaceuticals experienced a decline in its stock value following the failure of a late-stage clinical trial for a melanoma treatment.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
